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Human immunodeficiency virus type-1 (HIV-1) exhibits high between-host genetic
diversity and within-host heterogeneity, recognized as quasispecies. Because HIV-1
quasispecies fluctuate in terms of multiple factors, such as antiretroviral exposure and
host immunity, analyzing the HIV-1 genome is critical for selecting effective antiretroviral
therapy and understanding within-host viral coevolution mechanisms. Here, to obtain
HIV-1 genome sequence information that includes minority variants, we sought to
develop a method for evaluating quasispecies throughout the HIV-1 near-full-length
genome using the Illumina MiSeq benchtop deep sequencer. To ensure the reliability of
minority mutation detection, we applied an analysis method of sequence read mapping
onto a consensus sequence derived from de novo assembly followed by iterative
mapping and subsequent unique error correction. Deep sequencing analyses of aHIV-1
clone showed that the analysis method reduced erroneous base prevalence below
1% in each sequence position and discarded only <1% of all collected nucleotides,
maximizing the usage of the collected genome sequences. Further, we designed primer
sets to amplify the HIV-1 near-full-length genome from clinical plasma samples. Deep
sequencing of 92 samples in combination with the primer sets and our analysis method
provided sufficient coverage to identify >1%-frequency sequences throughout the
genome. When we evaluated sequences of pol genes from 18 treatment-naïve patients’
samples, the deep sequencing results were in agreement with Sanger sequencing
and identified numerous additional minority mutations. The results suggest that our
deep sequencing method would be suitable for identifying within-host viral population
dynamics throughout the genome.
Keywords: HIV-1, deep sequencing, drug resistance, error correction, consensus sequence estimation,
quasispecies
INTRODUCTION
Knowledge of the genome sequence of human immunodeficiency virus type-1 (HIV-1) is
fundamental for improving the clinical outcome of patients infected with HIV-1 and for
understanding viral co-evolution within hosts. However, not only between-host HIV-1 genetic
diversity and within-host viral heterogeneous population make it difficult to determine the viral
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sequences within host. HIV-1 is classified into four groups
(M, N, O, and P), and the group that is most widespread
globally, M, is further divided into nine subtypes (A, B,
C, D, F, G, H, J, and K), with more than 70 circulating
recombinant forms (CRFs), according to the Los Alamos HIV
Sequence database (http://www.hiv.lanl.gov/), and numerous
unique recombinant forms (URFs; Sharp, 2002; Taylor et al.,
2008; Hemelaar et al., 2011; Sharp and Hahn, 2011). Genetic
diversity between the subtypes ranges from 25 to 35% (Korber
et al., 2001), which is extremely high compared to the human
population, in which<1% of distinct DNA sequences are distinct
(International HapMap, 2003, 2004). This diversity is considered
a consequence of HIV-1’s short replication period, lack of
proofreading machinery, and recombination in viral replication
(Robertson et al., 1995; Perelson et al., 1996; Blackard et al., 2002).
The genetic diversity of HIV-1 likely influences the effectiveness
of antiretroviral therapy (Wainberg and Brenner, 2012) and
at least partially prevents the development of curable strategy
against HIV-1 infection (Thomson et al., 2002). Moreover, the
error-prone replication induces a within-host genetically diverse
heterogeneous viral population, recognized as quasispecies
(Ojosnegros et al., 2011). The quasispecies are considered a
source of drug-resistant or immune escape variants. Within-host
minority viruses likely influence clinical outcome (Johnson et al.,
2008; Balduin et al., 2009; Geretti et al., 2009; Metzner et al.,
2009; Simen et al., 2009; Paredes et al., 2010), although some
reports have found no association between treatment failure and
minority variants (Peuchant et al., 2008; Jakobsen et al., 2010;
Metzner et al., 2010; Stekler et al., 2011).
To improve clinical outcomes and further understand viral
co-evolution within-hosts, the HIV-1 RNA genome has been
sequenced using the direct Sanger sequencing method. For
example, before treatment against HIV-1 infection, the pol and
env V3 regions are sequenced in genotyping resistance tests and
tropism tests that predict viral susceptibility to antiretroviral
drugs (Smit, 2014). However, analysis of viral polymorphic
sequences is limited using Sanger sequencing method. For
example, direct Sanger sequencing is inappropriate for analyzing
regions containing heterogeneous insertions or deletions, such as
gag and env. Within-host quasispecies population analyses using
direct Sanger sequencing can detect low-frequency mutations
in only up to 10–20% of the population. In addition, primer
design may be troublesome when analyzing sequences of large
or multiple segments.
Recently developed next-generation sequencing technologies
that output unprecedented amounts of short sequence reads
enable the analysis of viral quasispecies in further depth (Willerth
et al., 2010; Dudley et al., 2012; Gall et al., 2012; Henn et al.,
2012; Gibson et al., 2014; Park et al., 2014). Bench-top deep
sequencers Roche/454 GS Junior and Ion PGM, both based on
the pyrosequencingmethod, are applicable for analyses of limited
regions of the HIV-1 genome (Dudley et al., 2012; Gibson et al.,
2014; Park et al., 2014). Illumina has released another bench-top
deep sequencer, MiSeq, based on bridge sequencing technology,
which, compared with the aforementioned pyrosequencing
platforms, can output large amounts of sequence reads with a
lower intrinsic error rate, especially at homopolymeric regions,
including the drug-resistance-related reverse transcriptase (RT)
K65 codon (Varghese et al., 2010; Loman et al., 2012; Junemann
et al., 2013). Here, we have proposed a practical method to
analyze viral quasispecies of the HIV-1 near-full-length genome
in clinical samples using the Illumina MiSeq deep sequencing
method and especially evaluated nucleotide variations in viral
sequences of the Pol and the Env V3 encoding regions.
MATERIALS AND METHODS
Plasmid Sample Preparation
To examine analytical biases that may produce misleading results
and intrinsic errors in sequence reads from Illumina MiSeq,
pNL4-3 (pNL4-3wt) was used as a reference clone. Furthermore,
to examine the threshold of deep sequencing in detecting
minority mutations in clinical samples, artificially simulated
samples were prepared by mixing multiple different clones. For
this purpose, three pNL101-based recombinant infectious clones
(Neuveut and Jeang, 1996) possessing drug-resistance mutations
RT K103N (pNL101rtK103N), RT M184V (pNL101rtM184V),
and integrase (IN) Q148H (pNL101inQ148H) were constructed
using standard site-directed mutagenesis protocols as described
previously (Hachiya et al., 2008; Shimura et al., 2008).
Seven ratios of pNL4-3wt: pNL101rtK103N: pNL101rtM184V:
pNL101inQ148H were mixed as follows: (a) 100:0:0:0, (b)
99.97:0.01:0.01:0.01, (c) 99.7:0.1:0.1:0.1, (d) 98.5:0.5:0.5:0.5, (e)
97:1:1:1, (f) 70:10:10:10, and (g) 40:20:20:20.
Clinical Sample Collection and Sanger
Sequencing
Fifty-two plasma samples were collected from 33 HIV-1-infected
patients who visited the Nagoya Medical Center in Japan
from January 2009 to April 2014 (Supplementary Table S1).
Forty-five plasma samples collected from 25 patients enrolled
in the Japanese Drug Resistance HIV-1 Surveillance Network
(Gatanaga et al., 2007; Hattori et al., 2010; Shiino et al., 2014)
were also used in this study. Thus, a total of 97 plasma
samples obtained from 58 patients were used. To monitor viral
quasispecies chronologically, plasma samples were obtained at
10 time points from one patient failing protease inhibitors
(PIs) containing regimens. The total RNA was extracted from
200- or 400-µL of the plasma sample using the MagNA Pure
Compact Nucleic Acid Isolation Kit I (Roche Diagnostics K.K.,
Tokyo, Japan). Extracted RNA was eluted in a final volume of
50µL of elution buffer and used for subsequent analyses. HIV-
1 protease (PR) (297 bps; 2253–2549, positions based on HXB2
numbering), RT (720 bps; 2550–3269) and env V3 (108 bps;
7110–7217) sequences of each sample were analyzed using the
bulk sequencing method as previously reported (Gatanaga et al.,
2007; Hattori et al., 2010; Shiino et al., 2014). Drug-resistance
mutations in Pol were determined according to the list reported
by Shafer et al. (Bennett et al., 2009) and IAS-USA (Wensing
et al., 2014). HIV-1 subtypes were determined using phylogenetic
analysis with reference sequences recommended by the Los
Alamos Database (http://www.hiv.lanl.gov/). Genotypic tropism
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FIGURE 1 | Four overlapping segments covering the HIV-1
near-full-length genome. The blue numbers represent the 5′- and 3′-end
positions (HXB2 numbering) for RT-PCR, whereas red numbers show those for
nested PCR.
tests were performed using geno2pheno [coreceptor] (http://
coreceptor.geno2pheno.org/) with a false-positive rate of 10%.
This study was conducted according to principles in the
Declaration of Helsinki. The Ethical Committee at the National
Institute of Infectious Diseases and Nagoya Medical Center in
Japan approved the study. All patients provided written informed
consent for the collection of samples and subsequent analyses.
Amplification of the HIV-1 Near-full-length
Genome in Clinical Samples
To analyze the full-length HIV-1 genome (excluding LTR
regions) using MiSeq, the gag to nef (8825 bps; 706–9530) region
of the genome was amplified in four overlapping segments,
as shown in Figure 1. The primer sequences used for the
amplifications are listed in Supplementary Table S2. RT-PCR
was performed using a PrimeScript II High Fidelity One Step
RT-PCR Kit (Takara, Shiga, Japan), followed by nested PCR
using PrimeSTAR GXL DNA Polymerase (Takara, Shiga, Japan).
Finally, four amplified PCR products were combined into one
sample with a MultiScreen HTS PCR96 filter plate according
to the manufacturer’s instructions (Merck Millipore, Billerica,
Massachusetts, USA). The purified DNA was eluted into a final
volume of 50µL of distilled water.
Library Preparation and Deep Sequencing
with Illumina MiSeq
Viral DNA libraries for deep sequencing were prepared using
the Nextera DNA Sample Prep Kit (Illumina K.K.,Tokyo, Japan)
according to the manufacturer’s instructions. Unamplified DNA
of the recombinant clones and amplified DNA obtained from
clinical samples were used for the preparation. The prepared
library was sequenced using Illumina MiSeq, generating paired-
end 2× 250-bps-long sequence reads. For each run, a maximum
of 24 samples were concurrently examined.
Sequence Read Analysis for Deep
Sequencing
The sequence reads obtained from IlluminaMiSeq were analyzed
following three procedures: (I) mapping of the sequence reads
onto a reference sequence or a consensus sequence; (II) error
correction; and (III) frequency estimation of bases, amino acids,
or short (<250-bps-long) fragment sequences. The detailed
methods at each step are described below.
(I) Consensus Sequence Estimation and Read Mapping.
Sequence read mapping was conducted with the BWA-
MEM algorithm implemented in the BWA-0.6.4 program
(Li and Durbin, 2009, 2010) using the default setting.
We performed four sequence read mapping methods
(Supplementary Figure S1A) as follows:
(i) Simple mapping onto an infectious clone sequence.
The sequence reads were mapped on a given infectious
clone sequence, such as NL4-3, HXB2, JRCSF (GenBank
accession no. M38429) in subtype B, and 93JP-
NH1(NH1) in CRF01_AE (AB052995).
(ii) Mapping onto consensus sequence derived from de novo
assembly. Long fragments (>1000 bps) of the HIV-1
near-full-length genome sequence were assembled de
novo from sequence reads with the VICUNA program
(Yang et al., 2012; Malboeuf et al., 2013). The estimated
long fragment sequences were mapped onto the HXB2
sequence with the BWA program. Next, the long
fragment sequences were connected to construct a near-
full-length consensus sequence. Sequence reads were
then mapped onto the constructed consensus sequence.
(iii) Mapping onto consensus sequence estimated from
iterative mapping (McElroy et al., 2014; Verbist et al.,
2015). The first cycle of iterativemapping was performed
on a given reference sequence, such as NL4-3, HXB2,
JRCSF, or NH1, with BWA using an option of “-B 1”
to reduce mismatch penalty for mapping. The majority
base at each position was accepted as the consensus base.
In cases of insertions or deletions, the longer sequences
were always chosen for consensus sequence estimation;
i.e., deletions were ignored and insertions were accepted
regardless of their prevalence. The consensus sequence
estimated in the first cycle was used as a reference
sequence of the second cycle of iterative mapping with
the BWA program at the default setting. This procedure
was repeated nine times to refine a consensus sequence,
and, finally, the sequence reads were mapped onto
the consensus sequence obtained in the 9th iterative
mapping.
(iv) Combination of (ii) and (iii): Sequence reads were
mapped onto the consensus sequence estimated from de
novo assembly using the VICUNA program (Yang et al.,
2012; Malboeuf et al., 2013) followed by the iterative
mapping (McElroy et al., 2014; Verbist et al., 2015).
(II) Error Correction. We performed error correction using
averaged quality score (QS)-values for each reference
sequence position. The detailed method is described below.
(III) Frequency Estimation. We estimated the frequency of
each base at a given position by counting the number
of nucleotides for each base that remained after error
correction. We also calculated the occupancy of sequences
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within a <250-bps-long range because the maximum
length of Illumina MiSeq sequence reads is 250 bp. First,
we extracted short fragment sequences from the mapped
sequence reads within the targeted range. Then, identical
fragment sequences were grouped into a haplotype
sequence. The number of the fragment sequences was
counted for each haplotype sequence. Next, haplotype
sequences including bases of averaged QSs below 20 were
removed. The remaining haplotype sequences were used
for frequency estimation.
RESULTS
Use of the Consensus Sequence Estimated
from de novo Assembly or Iterative
Mapping Improved the Sequence Read
Mapping Results
To examine analytical bias that may produce misleading
results and an intrinsic error rate of output sequence reads
from Illumina MiSeq, pNL4-3wt was deeply sequenced in
quadruplicate. The obtained sequence reads from each of the
quadruplicate runs were individually mapped onto the original
pNL4-3wt sequence [Schema (i) in Supplementary Figure S1A].
The mapping results demonstrated >5000-fold coverage
throughout the HIV-1 genome (Figure 2, Supplementary
Figure S1B and Supplementary Table S3). To investigate the
effect of selected reference sequences on the mapping accuracy
and coverage of the sequence reads, two different subtype B
sequences, HXB2 (97.4% identical to NL4-3) and JRCSF (93.8%),
and one CRF01_AE sequence, NH1 (85.0%), were selected as
reference sequences for mapping [Schema (i) in Supplementary
Figure S1A]. As shown in Figure 2, the mapping coverage by
HXB2 (5722- to 23,058-fold) and JRCSF(3038- to 22,570-fold)
were comparable to that of NL4-3 (5424- to 21,616-fold), whereas
a considerable reduction in coverage was observed when NH1
was used as the reference sequence (0- to 21,064-fold). Thus,
selection of the reference sequence is clearly a critical factor
for accurate mapping and high coverage of deep sequencing
reads. However, for clinical samples, selection of an appropriate
reference sequence is problematic because the sample sequences
are unknown at the time of deep sequencing. To overcome
this problem, we estimated a consensus sequence from de novo
assembly, iterative mapping, or de novo assembly followed by
iterative mapping (Yang et al., 2012; Malboeuf et al., 2013; Gibson
et al., 2014; McElroy et al., 2014; Verbist et al., 2015) [Schema
(ii)–(iv) in Supplementary Figure S1A]. We used the resulting
consensus sequence as the reference sequence for mapping, as
previously proposed by others (Yang et al., 2012; Malboeuf et al.,
2013; Gibson et al., 2014; McElroy et al., 2014; Verbist et al.,
2015). The use of the de novo assembled consensus sequence
provided comparable mapping results (5731- to 23,053-fold) to
that of NL4-3. The assembled consensus sequence was analogous
to the original NL4-3 reference sequence but included ∼10 nef
mutations, suggesting that de novo assembly is likely insufficient
to estimate the true consensus sequence. By contrast, iterative
mapping or de novo assembly followed by iterative mapping
FIGURE 2 | Analytical biases at read mapping. The red and blue symbols
represent minimum and maximum coverage in the gag-nef region. The
sequence read coverage from four deep-sequencing runs is plotted using
squares, triangles, rhombuses, and circles.
estimated a consensus sequence that was identical to the NL4-3
sequence and resulted in the same mapping coverage as that
achieved using NL4-3 as the reference sequence. These results
suggest that iterative mapping and de novo assembly followed
by iterative mapping can estimate the true consensus sequence
and are most appropriate for sequence read mapping. Hence,
in the following sections, we mapped sequence reads from
deep sequencing using consensus sequence estimation by de
novo assembly followed by iterative mapping (Yang et al., 2012;
Malboeuf et al., 2013; Gibson et al., 2014; McElroy et al., 2014;
Verbist et al., 2015).
Our Unique Error-correction Method
Reduced the Prevalence of Erroneous
Bases Found in Sequence Reads for a
Recombinant Clone Below 1% in Each
Sequence Position
We also analyzed intrinsic errors in the sequence reads from deep
sequencing for pNL4-3wt. As shown in Figure 3A, without any
error-correction handling, evenwith clonal pNL4-3wt sequencing
results, the erroneous bases occupied a maximum of 6.4%
of the population at each reference sequence position. The
erroneous bases induced drug-resistance-associated mutations
such as IN T66A/I/K and Q148H/K/R at maximums of 1.7
and 1.6% of the population. Considering minority mutation
detection by deep sequencing, this error rate is excessive, making
minority-mutation determinations inaccurate. In analyzing the
patterns of errors, a dominant pattern was substitution (∼99.6%
in total errors), whereas insertions or deletions were not
frequently observed, as previously reported by others (Loman
et al., 2012; Junemann et al., 2013). Further examination of
substitution patterns revealed that C>A and T>G transversion
errors were most frequently observed in the pNL4-3wt sequence
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FIGURE 3 | Analytical bias in pNL4-3wt sequence reads from the Illumina MiSeq deep sequencer. (A) Frequencies of nucleotides with true bases (red dots)
and with erroneous bases (black dots) throughout the pNL4-3wt genome except for the LTR regions prior to any error correction. (B) Histogram of averaged QSs for
true bases and erroneous bases at each genome position. The averaged QSs for true bases are shown in red bars, whereas those for erroneous bases
occupying >0.5 and >1.0% of the population are represented as gray and black bars, respectively. In each range (x-axis) of the histogram, the four bars representing
results from each quadruplicate runs are shown. (C) Frequencies of nucleotides with true bases (red dots) and erroneous bases (black dots) throughout the pNL4-3wt
genome after error correction removed each base with averaged QSs below 20 at the respective position. (D) Error rate after error correction and the proportion of
removed nucleotides among all nucleotides using error correction. Results are shown for no error correction, quality-filtering error correction by removing nucleotides
with QSs below 20 or 30, and our error correction removing bases of averaged QSs below 20.
reads (Supplementary Figure S2). The predominance of T>G
transversion was previously reported for MiSeq (Schirmer et al.,
2015) and Illumina Genome Analyzer (Nakamura et al., 2011;
Flaherty et al., 2012), both of which are based on the bridge
sequencing method, suggesting that the transversion errors
might be intrinsic to the apparatuses and the technology.
To improve the accuracy of the sequencing results, we sought
to establish a novel error correction method by distinguishing
true minority bases from erroneous bases. To differentiate
true and erroneous bases, we focused on Phred QS-values of
nucleotides in pNL4-3wt sequence reads. QSs of 10, 20, and 30
indicate 90, 99, and 99.9% base-calling accuracy, respectively.
Nucleotides with true bases tend to demonstrate high QS-values,
whereas low QS-values are associated with erroneous bases
(Supplementary Figure S3). When the QSs of nucleotides with
true bases were averaged at the respective reference sequence
positions, the averaged QS-values for true bases were >25,
suggesting >99.7% base-calling accuracies (Figure 3B). By
contrast, when we focused on bases occupying >1% of the
population at the respective positions, the averaged QS-values
for erroneous bases were below 20 and were clearly different from
those for true bases at a threshold of 20 (Figure 3B). Thus, this
result indicates that “an averaged QS-value of 20” is a reasonable
cut-off threshold to distinguish true and erroneous bases.
Figure 3C shows the results of pNL4-3wt sequencing managed
by our novel error-correction method that removed bases with
averaged QS-values below 20 at each reference sequence position
(Supplementary Figure S3), and the erroneous bases did not
occupy >0.54% of the population. Especially, each population
of the drug resistant mutations in Pol and erroneous sequences
at Env V3 and PR cleavage sites in Gag, Pol, Nef (Shafer and
Schapiro, 2008; Fun et al., 2012) was not exceeded 0.2%. The
error rates were reduced to 0.017 ± 0.002 from 0.52 ± 0.098%
of the raw sequence reads (Figure 3D). Of note, our error-
correction method removed only <1% of all nucleotides
(Figure 3D), suggesting selective removal of erroneous
bases.
As a comparative method, we applied the simple quality-
filtering correction method reported by others (Dudley et al.,
2012; Gall et al., 2012; Pessoa et al., 2014) to the same pNL4-
3wt sequence reads. The quality-filtering method simply discards
any nucleotides with a QS below 20 or 30 as a cut-off value
(Supplementary Figure S3). This alternative method was also
successful in reducing error rates to 0.041 ± 0.006 and 0.026 ±
0.003% with a cut-off of QS < 20 and QS < 30, respectively
(Figure 3D). However, the quality-filtering method discarded 7%
and 11% of all nucleotides by the QS < 20 and QS < 30 cut-offs,
respectively (Figure 3D).
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FIGURE 4 | Deep sequencing to detect minority viral populations.
pNL4-3wt and pNL101-based mutant clones (pNL101rtK103N,
pNL101rtM184V, and pNL101inQ148H) were mixed at seven different ratios: (a)
100:0:0:0, (b) 99.97:0.01:0.01:0.01, (c) 99.7:0.1:0.1:0.1, (d) 98.5:0.5:0.5:0.5,
(e) 97:1:1:1, (f) 70:10:10:10, and (g) 40:20:20:20. The estimated frequencies
of RT K103N, RT M184V, and IN Q148H are shown in orange circles, red
squares, and black triangles, respectively.
Deep-sequencing Analyses Coupled with
Our Analysis Method for Distinct
Recombinant Clone Mixtures Successfully
Detected Minority Mutations with a
Prevalence of >1%
To confirm the potential of our mapping and error-correction
methods, we performed deep sequencings of mixtures of four
recombinant clones, pNL4-3wt, pNL101rtK103N, pNL101rtM184V,
and pNL101inQ148H in triplicate, at seven different ratios:
(a) 100:0:0:0, (b) 99.97:0.01:0.01:0.01, (c) 99.7:0.1:0.1:0.1, (d)
98.5:0.5:0.5:0.5, (e) 97:1:1:1, (f) 70:10:10:10, and (g) 40:20:20:20
(Figure 4, Supplementary Table S4). We successfully detected
three amino acid mutations stably in mixture samples when
mutant clones were mixed at ≥0.5% prevalence [(d)–(g)]. For
samples (b) and (c), where mutant clones were mixed at 0.01
and 0.1% prevalence, one and two in triplicate tests identified
the three mutations, respectively. During the amino acid
population analyses, our error-correction removed only ∼3% of
all three-nucleotide sequences. By contrast, the simple quality-
filtering correction method with a QS < 20 or QS < 30 cut-
off, removed ∼25 or 27% of all three-nucleotide sequences,
although the quality filtering correction method also allowed
us to stably detect three mutations in samples (d)–(g), where
mutant clones were mixed at ≥0.5% prevalence (Supplementary
Table S4). Taken together with the aforementioned results on
error prevalence, our analysis method enables us to detect amino
acid mutations at >1% of the population reproducibly and semi-
quantitatively while maximizing usage of the sequence read data.
Hence, in the following sections, errors in sequence reads
from deep sequencing were corrected with our error-correction
method based on averaged QS-values at a threshold of 20.
Furthermore, we used error-corrected >1%-frequency bases,
amino acids, or short <250-bps-long fragment sequences.
A Near-full-length Genome Amplification
Protocol was Successfully Constructed
We designed primer sets to amplify near-full-length viral RNA
genomes in four overlapping segments (Figure 1). A total of 97
clinical plasma samples were examined. Phylogeny analyses of
pol sequences derived from Sanger sequencing indicated that 58
plasma samples from 22 patients and 39 samples from 36 patients
contained subtype B and non-subtype B viral RNAs. The results
showed that all of the four segments were successfully amplified
for the subtype B samples with >200 copies/mL (Supplementary
Table S5). By contrast, two subtype B samples with 50 and 65.7
copies/mL were incompletely amplified with missing segments.
The same primer sets were tested for the remaining 39 non-
subtype B viruses, including 10 subtype C, 10 CRF01_AE, 9
subtype F, and 10 CRF02_AG HIV-1. We successfully amplified
all four segments for subtype C, CRF01_AE, subtype F, and
CRF02_AG viral genomes from samples with up to 432, 700,
2980, and 1600 copies/mL, respectively (Supplementary Table
S5). However, we failed to amplify three subtype F samples
below 1240 copies/mL, suggesting lower amplification efficacy
for non-subtype B viral genomes than subtype B genomes.
In particular, amplification of the in-env v5 regions in non-
subtype B genomes was relatively unsuccessful. This is likely due
to more nucleotide mismatches between the primer sequences
and non-subtype B viral genome sequences (Supplementary
Table S6). Further adjustment of these primers, especially for
the in-env v5 region, is required to improve amplification
for non-subtype B viral genomes and to effectively amplify
HIV-1 genomes regardless of their subtypes. Consequently,
all four segments were successfully amplified from 92 plasma
samples.
Subsequently, we deeply sequenced 92 amplified samples.
When we analyzed the obtained sequence reads, >95% of the
sequence reads were mapped onto the estimated consensus
sequence for each sample. Further, as shown in Supplementary
Figure S4, >1000-fold coverage of sequence reads were obtained
at each position throughout gag-nef, except for the 5′-end
of matrix in six samples, env in 1 sample, and the 3′-end
of nef in 1 sample (Supplementary Table S7). Therefore,
each minority nucleotide mutation occupying >1% of the
population was confirmed from at least 10 sequence reads.
Taken together, the results highlight that amplification with
our primer sets followed by deep sequencing enabled us to
analyze low-frequency mutations with sufficient sequence read
coverage.
Our Deep Sequencing Method Detected
more Minority Variants than the Direct
Sanger Sequencing Method
To evaluate the potential of detecting quasispecies and minority
population using our near-full-length deep sequencing method,
we compared the results obtained with the proposed method
and the direct Sanger sequencing method. We focused on
sequences at PR-RT encoding regions (1017 bps; 2253–3269)
from 18 treatment-naïve patients, including 13 subtype B, 4
CRF01_AE, and 1 CRF02_AG viruses (Supplementary Table
S1). We achieved both deep and Sanger sequencings from
the same amplicons. Only one mismatch was found in one
sample (TN07) between the consensus sequences derived using
the deep and Sanger sequencing methods (Figure 5A), except
216 positions in 18 samples where Sanger sequencing detected
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FIGURE 5 | Direct Sanger sequencing and deep sequencing
comparison of 18 treatment-naïve samples. (A) Identity of consensus
nucleotide sequences at positions where A, T, G, or C was detected by
Sanger sequencings between the two methods. (B) Correlation of
occupancies of bases at the positions where multiple bases at >1%
prevalence were detected by deep sequencings between the two methods.
For Sanger sequencing, occupancies of bases were estimated from their
electropherogram peak heights. Black dots show mixture bases assigned from
Sanger sequencing electropherograms. Red dots show mixture bases that
were unassigned by Sanger sequencing but were identified by the deep
sequencing method. Bottom graphs represent histograms of occupancies
detected by the deep sequencing method. The black and red bars show
incident rates detected by Sanger sequencings and those detected only by
deep sequencing methods, respectively.
mixture bases. Thus, the concordance rate of the two methods
was 99.994% [one mismatch in 18,090 (1017 × 18 – 216)
positions]. Furthermore, we evaluated the sensitivity of the
deep and Sanger sequencing methods in detecting minority
populations. For Sanger sequencing, base occupancies were
calculated from the electropherogram peak height ratios. As
shown in Figure 5B, when base occupancies were analyzed at
the 216 positions where Sanger sequencing detected mixture
bases, a good correlation was observed between the Sanger
sequencing method and deep sequencing method (1143 peaks,
R2 = 0.76, P < 0.0001, single regression analysis; black
dots in Figure 5B), and all mixture bases detected with
Sanger sequencings were identified with the deep sequencing
method. However, using the deep sequencing method, we
detected an additional 1069minority bases in all 18 samples
that Sanger sequencing failed to recognize (red dots in
Figure 5B). These results suggest that deep sequencing is more
sensitive in detecting minority variants than Sanger sequencing
and enables us to analyze quasispecies in clinical samples
semi-quantitatively. These additional minority bases contained
substitutions conferring drug resistance, and PR M46I (1.1%
in TN03, 3.8% in TN04), RT T215S (1.0% in TN01), and RT
K219R (1.2% in TN04) were identified. Thus, deep sequencing
is likely useful in determining effective treatment regimen in
clinical settings.
Our Deep Sequencing Method is
Applicable for Detecting Minority X4-tropic
Viruses and Examining the Chronological
Population Dynamics of Quasispecies
To confirm the clinical advantages of deep sequencing, we
applied our deep sequencing method in genotypic tropism
testing to determine the co-receptor usage of 18 treatment-
naïve patients’ samples (Supplementary Figure S5). The deep
sequencing method identified heterogeneous V3 sequences
in each sample (Supplementary Table S8) and identified
nine samples possessing X4-tropic viruses, whereas only 5
samples were identified using Sanger sequencing. As shown in
Supplementary Figure S5, all X4 tropic viral sequences in four
samples diagnosed using the deep sequencing had less than a 20%
minority population (Supplementary Table S8). Thus, the deep
sequencing is more sensitive in detecting minority X4-tropic
viruses than Sanger sequencings.
To confirm whether our deep sequencing method allows
us to dissect quasispecies population dynamics and identify
minority drug-resistance mutations relevant to treatment
failure, we retrospectively monitored changes in drug-
resistance-related mutations in one multi-drug-resistant
case (PI-resistant patient #1 in Supplementary Table S1) with
M41L/D67N/T69D/M184V/L210W/T215Y in the RT region
and M46IL/G73S/I84V/L90M in the PR region (Figure 6). We
analyzed 10 time points and found that under an EFV-based
regimen (time points 3–6), the prevalence of non-nucleoside
RT inhibitor (NNRTI)-resistant mutations L100I and K103N
increased from <1 to 89.2% and 17.7 to 95.2%, respectively, with
viral load relapse from 500 (time point 3) to 5400 copies/mL
(time point 5). At time point 6 with 7200 copies/mL, the
population of the other NNRTI-resistant mutations, Y181C
(33.3%) and G190S (36.4%) increased, whereas the prevalence of
L100I and K103N decreased (58.3 and 59.5%). These NNRTI-
mutations became undetectable after the regimen was switched
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to LPV/r-based therapy (time points 7–10). Emergence of PR
I54L followed by I54V was also correlated with relapse under
LPV/r-based therapy. Thus, the dynamic population movements
of drug-resistance mutations were successfully monitored in
detail using our deep sequencing method. In addition to drug-
resistance mutations, we also found a population possessing
the NC/p1 cleavage-site mutation AP2V was fluctuating with
the regimen switches, when we analyzed the sequences at all
11 PR cleavage sites in Gag, Pol, and Nef (Shafer and Schapiro,
2008; Fun et al., 2012). The mutation was first identified as the
major population at time point 1, when SQV-based therapy
was in progress. Subsequently, the mutation became a minority
with EFV-based therapy, and revived as the majority with
LPV/r-based therapy.
Although clinical significance was not confirmed in these
two analyses of tropism testing and drug resistance mutation
monitoring, our results suggest that our deep sequencing
method for clinical sample analysis generates more data for
understanding within-host viral co-evolutions such as tropism
drifting and selection of antiretroviral resistances.
DISCUSSION
In this study, we have proposed a practical method to analyze
viral quasispecies of the HIV-1 near-full-length genome in
clinical samples using the Illumina MiSeq deep sequencing
method (Supplementary Figure S6). Sequence data with low error
rates are crucial for accurately analyzing minority populations
and genetic diversity of HIV-1. We applied a unique error
correction to minimize the effect of artificial errors and facilitate
HIV-1 genome analysis using the Illumina bridge sequencing
technology. Of note, Illumina bridge sequencing produces
0.52 ± 0.098% reading errors, which is significantly greater
than sequencing platforms using high-fidelity polymerases (Cline
et al., 1996; Palmer et al., 2005), but lower than pyrosequencing
methods exhibiting high error rates at homopolymeric regions
(Varghese et al., 2010; Dudley et al., 2012; Loman et al.,
2012; Di Giallonardo et al., 2013; Junemann et al., 2013;
Gibson et al., 2014). Our sequencing analysis of the infectious
clone pNL4-3wt indicated that the averaged QS-value is a
reasonable guide to distinguish true and erroneous bases.
One advantage of our error-correction method based on
the averaged QS-value is that it removes significantly fewer
nucleotides than quality-filtering error correction methods
previously reported (Dudley et al., 2012; Gall et al., 2012; Pessoa
et al., 2014), which increases the opportunity for detecting
minority mutations.
In addition, sequencing analysis of the pNL4-3wt clone
suggested that reference sequence choice is critical for accurate
and efficient sequence read mapping. To select an appropriate
reference sequence in clinical sample analyses, we found that
consensus sequence estimated from sequence reads is applicable
as the reference sequence for the mapping as reported previously
by others (Yang et al., 2012; Malboeuf et al., 2013; McElroy
et al., 2014; Verbist et al., 2015), and that de novo assembly
followed by iterative mapping [Schema (iv) in Supplementary
Figure S1A] precisely estimates consensus sequence. During
sequence analysis at PR-RT encoding regions of treatment-
naïve patients’ samples, de novo assembly followed by iterative
mapping estimated the same consensus sequence as Sanger
sequencing, except for one mutation in TN07 (Figure 5). By
contrast, another estimation method, de novo assembly [Schema
(ii) in Supplementary Figure S1A] inferred consensus sequences
with two mutations for TN11 and another mutation for
TN07.
When we performed phylogeny analyses of these estimated
near-full-length consensus sequences for each clinical sample,
their phylogenetic tree showed concordant subtypes to those
based on their pol sequences by Sanger method (Supplementary
Figure S7), except two samples (Non-subtype B samples #23
and #26 in Supplementary Table S1). Although these two samples
were classified into CRF02_AG from the pol and of subtype A
or G from the near-full-length sequences, this is likely due to
analyzed sequence lengths and/or recombination breakpoint
positions within CRF02_AG. Furthermore, phylogenetic clusters
were found among samples from each drug-resistant patient.
Samples from a partner pair (TN12 and TN13) diagnosed
in our hospital were also phylogenetically close to each
other. Taken together with high sequence identities of the
Pol and Env V3 encoding regions between Sanger and our
methods, these results suggest that our method may estimate
consensus sequences throughout near-full-length regions
accurately.
With our error-correction and mapping methods, we can
obtain benefit of large genome information from the bridge
sequencing. Our method enables both in-depth and semi-
quantitative quasispecies analyses (Figure 5 and Supplementary
Figure S5). Although we especially evaluated sequences at the
Pol and Env V3 encoding regions in this study, our method
would be applicable for quasispecies analyses at the other
regions such at PR cleavage sites as shown in Figure 6. This
is an advantage of our method that is applicable to analyze
sequences throughout near-full-length genomes in depth at a
run, unlike Sanger or allele specific sequencing methods. Of note,
we successfully amplified genomes from low viral load samples
using our designed primer sets. Therefore, when patient’s viral
load increases above the detection limit, our method might be
helpful for early detection of drug resistant mutations. Collecting
and analyzing genome date using our methods will lead to
a comprehensive understanding of unknown mechanisms of
resistance acquisition and treatment failure, such as the recent
finding demonstrating the importance of the Env cytoplasmic
tail mutation in PI resistance (Rabi et al., 2013). Moreover,
our method would also be applicable to examine whether
drug resistant variants are persistent as proviral DNA, although
further assessment is required. Combination of in vitro resistance
induction experiments or in vivo infection of HIV-1 relatives
to animal models with our method would help recognize drug
resistant machinery or viral evolution. However, there are at least
two limitations with our analysis method. The first is due to short
sequence reads. Because sequence reads in our study were up to
250-bps long, it was difficult to evaluate interferences of two or
more mutations that locate more than 250-bps distant positions.
Despite the limitation, our deep sequencing method could help
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FIGURE 6 | Application of our deep sequencing method in examination of chronological population changes of drug-resistance mutations.
Chronological changes in viral loads, CD4+ T-cell counts, and occupancies of drug-resistance mutations for a patient who failed a PI-containing regime. In the left
graph, viral loads and CD4+ T-cell counts are shown in black and light red lines, respectively. Collection dates of analyzed samples are highlighted in orange
perpendicular lines. Over the orange line, the identification numbers for the collection dates are also shown. At the top of the graph, periods when drugs were used
are shown in horizontal bars. Furthermore, population dynamics of resistance related mutations are shown on the right of the graph. The occupancies of the
mutations are highlighted with colors according to the bottom bar. PI, PR inhibitor; NRTI, nucleoside/nucleotide RT inhibitor; NNRTI, non-nucleoside RT inhibitor. IDV,
indinavir; NFV, nelfinavir; SQV, saquinavir; RTV, ritonavir; LPV/r, lopinavir boosted with ritonavir; AZT, azidothymidine; 3TC, lamivudine; d4T, stavudine; EFV, efavirenz.
obtain hints to know co-evolution within the genome, like
mutations in PR and its cleavage sites, in combination with clonal
sequencings or haplotype inference by recently proposed some
bioinformatics algorithms (Beerenwinkel and Zagordi, 2011;
Beerenwinkel et al., 2012; Prosperi et al., 2013; Giallonardo et al.,
2014; Schirmer et al., 2014; Jayasundara et al., 2015). The second
limitation is attributable to limited stocks of plasma viral RNAs.
In several clinical samples, cDNA was amplified from 2.5µL
of extracted viral RNA for each of the four segments, which
theoretically contained less than 100 copies of viral RNA, as the
original 200µL plasma had a viral load of <5000 copies/mL.
This limitation alerts that the results might be less heterogeneous
population than in reality, although we attempted to reduce this
risk by triplicate genome amplifications for deep sequencing of
each sample. To address this second limitation, in addition to
triplicate genome amplification, we must consider increasing
several parameters, including the amount of templates, viral
RNA, plasma, PCR volume, interestingly retrogressing direction
of downsizing sequence technology progress in the last decade.
In conclusion, we devised a data management method and
library preparation protocol to analyze quasispecies throughout
the HIV-1 near-full-length genome using Illumina MiSeq
bentchtop deep sequencing technology. Using deep-sequencing
technology with larger genome datasets to precisely analyze
minority drug-resistance mutations may improve the efficacy of
antiretroviral therapy management in clinical settings.
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